JP4939401B2 - TAFIa阻害剤として用いるイミダゾール誘導体 - Google Patents

TAFIa阻害剤として用いるイミダゾール誘導体 Download PDF

Info

Publication number
JP4939401B2
JP4939401B2 JP2007508756A JP2007508756A JP4939401B2 JP 4939401 B2 JP4939401 B2 JP 4939401B2 JP 2007508756 A JP2007508756 A JP 2007508756A JP 2007508756 A JP2007508756 A JP 2007508756A JP 4939401 B2 JP4939401 B2 JP 4939401B2
Authority
JP
Japan
Prior art keywords
imidazol
alkyl
unsubstituted
twice
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007508756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007533672A5 (enExample
JP2007533672A (ja
Inventor
クリストファー・カールス
ホルガー・ハイチュ
アンドレーアス・リンデンシュミット
スヴェン・グリューネベルク
ハウケ・シラト
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4939401(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2007533672A publication Critical patent/JP2007533672A/ja
Publication of JP2007533672A5 publication Critical patent/JP2007533672A5/ja
Application granted granted Critical
Publication of JP4939401B2 publication Critical patent/JP4939401B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2007508756A 2004-04-22 2005-04-07 TAFIa阻害剤として用いるイミダゾール誘導体 Expired - Fee Related JP4939401B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004020186.2 2004-04-22
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla
PCT/EP2005/003630 WO2005105781A1 (de) 2004-04-22 2005-04-07 Imidazol-derivate als tafia-inhibitoren

Publications (3)

Publication Number Publication Date
JP2007533672A JP2007533672A (ja) 2007-11-22
JP2007533672A5 JP2007533672A5 (enExample) 2008-05-08
JP4939401B2 true JP4939401B2 (ja) 2012-05-23

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007508756A Expired - Fee Related JP4939401B2 (ja) 2004-04-22 2005-04-07 TAFIa阻害剤として用いるイミダゾール誘導体

Country Status (34)

Country Link
EP (2) EP1740569B1 (enExample)
JP (1) JP4939401B2 (enExample)
KR (1) KR101162047B1 (enExample)
CN (1) CN100572376C (enExample)
AR (1) AR053302A1 (enExample)
AT (2) ATE386737T1 (enExample)
AU (1) AU2005238144B2 (enExample)
BR (1) BRPI0510159A (enExample)
CA (1) CA2563401C (enExample)
CR (1) CR8650A (enExample)
CY (1) CY1108087T1 (enExample)
DE (2) DE102004020186A1 (enExample)
DK (1) DK1740569T3 (enExample)
EC (1) ECSP066941A (enExample)
ES (1) ES2299026T3 (enExample)
HR (1) HRP20080099T3 (enExample)
IL (1) IL178672A (enExample)
MA (1) MA28543B1 (enExample)
MY (1) MY140903A (enExample)
NI (1) NI200600217A (enExample)
NO (1) NO20065320L (enExample)
NZ (1) NZ550757A (enExample)
PE (1) PE20060172A1 (enExample)
PL (1) PL1740569T3 (enExample)
PT (1) PT1740569E (enExample)
RS (1) RS50553B (enExample)
RU (1) RU2375356C2 (enExample)
SI (1) SI1740569T1 (enExample)
TN (1) TNSN06341A1 (enExample)
TW (1) TWI359016B (enExample)
UA (1) UA87306C2 (enExample)
UY (1) UY28868A1 (enExample)
WO (1) WO2005105781A1 (enExample)
ZA (1) ZA200607668B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2104497T1 (sl) 2006-12-06 2015-06-30 Sanofi Derivati sulfamida kot inhibitorji TAFIa
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008100459A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
CA2693169C (en) 2007-07-19 2016-01-12 Metabolex, Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
US8580777B2 (en) * 2008-06-06 2013-11-12 Sanofi Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa
CA2741783A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having tafia inhibitory activity
RS52963B (sr) * 2009-05-15 2014-02-28 Sanofi Postupak za dobijanje jedinjenja koje je korisno kao inhibitor tafia
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
BR112012023412A2 (pt) 2010-03-18 2018-05-08 Daiichi Sankyo Company, Limited composto, drogra farmacêutica, inibidor de tafia, promotor de fibrinólise, droga preventiva ou terapêutica, composição farmacêutica, e, uso de um composto.
NZ601658A (en) 2010-03-18 2014-08-29 Daiichi Sankyo Co Ltd Cycloalkyl-substituted imidazole derivative
BR112013011244A2 (pt) * 2010-11-11 2017-10-24 Sanofi Sa processo para a preparação de derivados e ácido 3-(6-amino-piridin-3il)-2-acrílico
US9145385B2 (en) 2011-11-25 2015-09-29 Sanofi Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexy1-1H-imidazol-4-yl)-propionic acid
WO2013076177A1 (de) 2011-11-25 2013-05-30 Sanofi Salz von (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl)- propionsäureethylester
US9102657B2 (en) * 2011-11-25 2015-08-11 Sanofi Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
SG11201509144YA (en) 2013-06-10 2015-12-30 Sanofi Sa MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFI<sb>A</sb>, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
EP3437641A4 (en) 2016-03-29 2019-11-20 Daiichi Sankyo Company, Limited THERAPEUTIC AGENT AGAINST INFLAMMATORY DARMER DISEASE
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69937307T2 (de) * 1998-12-24 2008-02-07 Astellas Pharma Inc. Imidazol verbindungen und ihre medizinische verwendung
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
WO2003061653A1 (en) 2002-01-22 2003-07-31 Pfizer Limited 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases

Also Published As

Publication number Publication date
AR053302A1 (es) 2007-05-02
ATE523505T1 (de) 2011-09-15
CA2563401A1 (en) 2005-11-10
ECSP066941A (es) 2006-12-20
RU2375356C2 (ru) 2009-12-10
KR101162047B1 (ko) 2012-07-04
TWI359016B (en) 2012-03-01
PE20060172A1 (es) 2006-03-31
EP1740569A1 (de) 2007-01-10
NO20065320L (no) 2007-01-12
ES2299026T3 (es) 2008-05-16
IL178672A (en) 2011-08-31
PL1740569T3 (pl) 2008-07-31
KR20070007346A (ko) 2007-01-15
NZ550757A (en) 2010-06-25
RU2006141246A (ru) 2008-06-10
SI1740569T1 (sl) 2008-06-30
CN1950357A (zh) 2007-04-18
CN100572376C (zh) 2009-12-23
JP2007533672A (ja) 2007-11-22
EP1740569B1 (de) 2008-02-20
ATE386737T1 (de) 2008-03-15
UY28868A1 (es) 2005-11-30
PT1740569E (pt) 2008-03-31
RS50553B (sr) 2010-05-07
CR8650A (es) 2007-12-04
DE102004020186A1 (de) 2005-11-17
IL178672A0 (en) 2007-02-11
ZA200607668B (en) 2008-03-26
CA2563401C (en) 2012-08-07
AU2005238144A1 (en) 2005-11-10
DE502005002927D1 (de) 2008-04-03
AU2005238144B2 (en) 2010-08-26
CY1108087T1 (el) 2014-02-12
MA28543B1 (fr) 2007-04-03
EP1864979B1 (de) 2011-09-07
HRP20080099T3 (en) 2008-03-31
NI200600217A (es) 2008-06-17
HK1101823A1 (zh) 2007-10-26
TNSN06341A1 (en) 2008-02-22
MY140903A (en) 2010-01-29
BRPI0510159A (pt) 2007-10-02
UA87306C2 (en) 2009-07-10
TW200602325A (en) 2006-01-16
EP1864979A1 (de) 2007-12-12
DK1740569T3 (da) 2008-06-02
WO2005105781A1 (de) 2005-11-10

Similar Documents

Publication Publication Date Title
JP4939401B2 (ja) TAFIa阻害剤として用いるイミダゾール誘導体
JP4861306B2 (ja) Xa因子阻害剤としてのピロール誘導体
JP4585448B2 (ja) 第Xa因子阻害剤としてのピラゾール−誘導体
WO2003013526A1 (en) Anticoagulant compounds
JP4709763B2 (ja) 第Xa因子阻害剤としてのインダゾール誘導体
EP1358178A2 (en) Sulfonamide lactam inhibitors of factor xa
US8044208B2 (en) Imidazole derivatives as inhibitors of TAFIa
US8710232B2 (en) Imidazole derivatives used as TAFIa inhibitors
JP4608495B2 (ja) 第Xa因子阻害剤としてのトリアゾール誘導体
JP2005506970A (ja) 置換イソインドール類およびそれらの使用
JP4504820B2 (ja) Xa因子阻害剤としてのイミダゾール誘導体
JP4658940B2 (ja) 第Xa因子阻害剤としてのベンゾイミダゾール誘導体
MXPA06011067A (en) Imidazole derivatives used as tafia inhibitors
KR101373533B1 (ko) 인자 Xa 억제제로서의 헤테로아릴-카복실산(설파모일 알킬)아미드 유도체
HK1101823B (en) Imidazole derivatives used as tafia inhibitors
JP2006527728A (ja) Xa因子の阻害剤としての2−ピロリドン誘導体およびその使用
KR20060136457A (ko) 인자 Xa 억제제로서의 피롤-유도체
JPWO2000078747A1 (ja) アシルヒドラジン誘導体、その製造法及び用途
AU2002248391A1 (en) Sulfonamide lactam inhibitors of factor XA
JPWO1999033805A1 (ja) 環状アミノ基を有する芳香族化合物またはその塩
MXPA99007603A (en) Antitromboti agents
JPWO1999040075A1 (ja) スルホンアミド誘導体、その製造法及び用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120131

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120224

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150302

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees